Apellis Pharmaceuticals (APLS)
(Delayed Data from NSDQ)
$37.66 USD
+4.07 (12.12%)
Updated Aug 8, 2024 04:00 PM ET
After-Market: $37.58 -0.08 (-0.21%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth F Momentum D VGM
Brokerage Reports
Apellis Pharmaceuticals, Inc. [APLS]
Reports for Purchase
Showing records 21 - 40 ( 294 total )
Company: Apellis Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Takeaways From Our Conversation With Apellis Pharmaceuticals Management; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Apellis Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Apellis Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Apellis Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
With Vasculitis Fading to Black, the Growth Story Comes Into Focus; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Apellis Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Apellis Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Shifting The Focus Towards Europe As Re-Examination Proceeds
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Apellis Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Apellis Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Apellis Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Apellis Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Apellis Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
As Anticipated, CHMP Issues Negative Opinion for Syfovre
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Apellis Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Syfovre Definitely Has Its Mojo Back; Target to $92
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Apellis Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Apellis Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Revisiting Syfovre Trajectory Following APLS'' Latest Preannouncement
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Apellis Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Apellis Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Apellis Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Despite Some Ups and Downs, Syfovre Looks Headed Straight Up Once Again; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Apellis Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
CHMP Unimpressed With Functional Arguments For Pegcetacoplan
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Apellis Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
No European Vacation For Pegcetacoplan in GA; We Remain Buyers
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D